Isofol provides update on the AGENT study
GOTHENBURG, Sweden, August 31, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announced that, having received access to […]
English
Isofol Medical AB (publ) publishes interim report, January–June 2022
GOTHENBURG, Sweden, August 23, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report
Invitation to presentation of Isofol´s report for the second quarter of 2022
GOTHENBURG, Sweden, August 15, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for
Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints
GOTHENBURG, Sweden, August 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the
Isofol receives approval of biomarker analysis patent and intention-to-grant patent application for study dose regimen in Europe
GOTHENBURG, Sweden, July 26, 2022 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), today announced the European approval for a
Isofol updates start time of live-streamed R&D event on June 20 to 14:00 CEST
GOTHENBURG, Sweden, June 17, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the company is postponing
Isofol invites to a live-streamed R&D Event on June 20 at 12.30 CEST
GOTHENBURG, Sweden, June 14, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the company invites investors,
Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19, 2022
Today on May 19, 2022 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting
Isofol Medical AB (publ) publishes interim report, January–March 2022
GOTHENBURG, Sweden, May 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report
Invitation to presentation of Isofol’s report for the first quarter of 2022
GOTHENBURG, Sweden, May 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for